Cardiac injury and COVID-19: A Review on available present-day literature

Authors

  • Padma V
  • Rameez B. Raja
  • Abhilash B. Nair

DOI:

https://doi.org/10.51248/.v40i4.308

Keywords:

Heart failure, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), corona virus disease, Angiotensin converting enzyme, injuries, angiotensin converting enzyme inhibitor (ACEi) /angiotensin receptor blocker (ARB)

Abstract

What started as a small cluster of viral pneumonia like cases in a province of China, in the early weeks of December, has blown out to be a full-fledged pandemic virtually affecting every continent. PubMed and Google search engines were used for literature search. The case fatality rate which is around 2.6% for corona virus disease (COVID-19) patient’s rise to nearly 10.6% in COVID-19 patients with prior cardio vascular disease. Common cardiac manifestations include heart failure and myocardial damage. Angiotensin converting enzyme (ACE2) plays an important part in the pathophysiology of heart function in hypertension and diabetes, two of the most common manifestations of heart failure and is the cellular entry point for the severe acute respiratory syndrome (SARS) virus. Patients with cardio vascular disease are believed to have increased secretion of ACE2 compared to healthy individuals and thus are at higher risk. Patients on medications with angiotensin converting enzyme inhibitor (ACEi) /angiotensin receptor blocker (ARB) have increased ACE2 levels and may be at an increased risk, however there is no statistically significant data to substantiate this claim.

Author Biographies

Padma V

Professor, Department of Medicine, Sree Balaji Medical College and Hospital, Chennai, India

Rameez B. Raja

Assistant Professor, Department of Medicine, Sree Balaji Medical College and Hospital, Chennai, India

Abhilash B. Nair

Junior Resident, Department of Medicine, Sree Balaji Medical College and Hospital, Chennai, India

References

Virchow, R. Die Cellularpathologie in Ihrer Begründung auf Physiologische und Pathologische Gewebelehre. Hirschwald; 1858.

Mann, D. L., Chakinala, M. Heart Failure: Pathophysiology and Diagnosis; Harrisons Principles of Internal Medicine; 20th edition. 1763-1768.

Kuiken, T., Fouchier, R. A. M., Schutten, M., Rimmelzwaan, G. F., Amerongen, G., Riel, D., et al., Newly discovered corona virus as the primary cause of severe acute respiratory syndrome. Lancet 2003; 362: 263-270.

De Groot, R. J., Baker, S. C., Baric, R. S., Brown, C. S., Drosten, C., Enjuanes, L., et al., Middle East respiratory syndrome corona virus (MERS-CoV): announcement of the Corona virus Study Group. J Virol. 2013; 87: 7790-7792.

World Health Organization (WHO) Emergency Committee. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel corona virus (2019-nCoV). Geneva: WHO; 30 January 2020.

WHO situation reports 209 https://www.who.int/docs /defaultsource/coronaviruse/situation-reports/20200816-covid-19sitrep209.pdf?sfvrsn=5dde1ca 2_2

WHO report. Transmission of SARS-CoV-2. implications for infection prevention precautions; Scientific Brief; 09/07/2020.

Zheng, Y. Y., Ma, Y. T., Zhang, J. Y., and Xie, X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020, 10.1038/s41569-020-0360-5.

Xiong, T. Y., Redwood, S., Prendergast, B., Chen, M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020, 10.1093/eurheartj/ehaa231.

Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., et al., Risk factors associated with acute respiratory distress syndrome and death in patients with corona virus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020, 10.1001/jamainternmed.2020.0994.

Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., et al., Prevalence of co morbidities and its effects in corona virus disease 2019 patients: A systematic review and meta-analysis. Int J Infect Dis. 2020; 94: 91-95.

Arentz, M. Y. E., Klaff, L., Lokhandwala, S., Riedo, F. X., Chong, M., Lee, M. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020, 10.1001/jama.2020.4326.

Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al., Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Corona virus-Infected Pneumonia in Wuhan, China. JAMA. 2020, 10.1001/jama.2020.1585.

Mehra, M. R., Desai, S. S., Kuy, S., Henry, T. D., Patel, A. N. Cardiovascular Disease, Drug Therapy, and Mortality in COVID-19. N Engl J Med. 2020, 10.1056/NEJMoa2007621.

Mo, P., Xing, Y., Xiao, Y., Deng, L., Zhao, Q., Wang, H., et al., Clinical characteristics of refractory COVID-19 pneumonia in Wuhan,China. Clin Infect Dis. 2020, 10.1093/cid/ciaa270.

Inciardi, R. M., Adamo, M., Lupi, L., Cani, D. S., Di Pasquale, M., Tomasoni, D., Italia, L., et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. European heart journal. 2020 May 14;41(19):1821-1829.

Klein, S. L., Flanagan, K. L. Sex differences in immune responses. Nat Rev Immunol. 2016; 16: 626-638.

Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., et al., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA internal medicine. 2020 Mar 13.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020 Feb 15;395(10223): 497-506.

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., et al., Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study; VOLUME 395, ISSUE 10229, P1054-1062, MARCH 28, 2020; The Lancet.

Hu, H., Ma, F., Wei, X., Fang, Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. European heart journal. 2020 Mar 16.

Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G., et al., Clinical characteristics of 113 deceased patients with corona virus disease 2019: retrospective study. BMJ. 2020; 368:m1091.

Dong, N., Cai, J., Zhou, Y., Liu, J., Li, F. End-stage Heart Failure with COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV. JACC Heart Fail. 2020, 10.1016/j.jchf.2020.04.001.

Inciardi, R. M., Lupi, L., Zaccone, G., Italia, L., Raffo, M., Tomasoni, D., et al., Cardiac Involvement in a patient with Corona virus Disease 2019 (COVID-19). JAMA Cardiology. 2020, 10.1001/jamacardio.2020.1096.

Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., et al., Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8: 420-422.

Zhou, R. Does SARS-CoV-2 cause viral myocarditis in COVID-19 patients? Eur Heart J. 2020, 10.1093/eurheartj/ehaa392.

Ding, Y., Wang, H., Shen, H., Li, Z., Geng, J., Han, H., et al., The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol 2003; 200: 282-289.

Hamming, I., Timens, W., Bulthuis, M. L. C., Lely, A. T., Navis, G. J., Goor, H. Tissue distribution of ACE2 protein, the functional receptor for SARS corona virus. A first step in understanding SARS pathogenesis; J Pathol. 2004 Jun; 203(2): 631–637.

Chen, L., Li, X., Chen, M., Feng, Y., Xiong, C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020; 116: 1097-1100.

Flammer, A. J., Anderson, T., Celermajer, D. S. The assessment of endothelial function: from research into clinical practice. Circulation. 2012; 126: 753-767.

Klok, F. A., Kruip, M., Meer, N. J. M., Arbus, M. S., Gommers, D.A.M.P.J., et al., Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020, 10.1016/j.thromres.2020.04.013.)

Takasu, O., Gaut, J. P., Watanabe, E., To, K., Fagley, R. E., Sato, B., et al., Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. Am J Respir Crit Care Med. 2013; 187: 509-517.

Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., et al., Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis. 2020 doi: 10.1093/cid/ciaa248.

Adão, R. Inside the heart of COVID-19. Cardiovasc. Res. 2020 doi: 10.1093/cvr/cvaa086.

Chen, D., Li, X., Song, Q., Hu, C., Su, F., Dai, J. Hypokalemia and clinical implications in patients with corona virus disease 2019 (COVID-19) medRxiv. 2020 doi: 10.1101/2020.02.27.20028530.

Li, S. S., Cheng, C. W., Fu, C. L., Chan, Y. H., Lee, M. P., Chan, J. W. Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study. Circulation. 2003; 108: 1798-1803.

Chen, C., Jiangtao, Y., Ning, Z., Jianping, Z., Daowen, W. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. Chinese J Cardiol. 2020; 48: E008.

Cameron, M. J., Bermejo-Martin, J. F., Danesh, A., Muller, M. P., Kelvin, D. J. Human immunopathogenesis of severe acute respiratory syndrome (SARS) Virus Res. 2008; 133: 13-19.

Wong, C. K., Lam, C. W., Wu, A. K., Lp, W. K., Lee, N. L. S., et al., Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 2004; 136: 95-103.

Babapoor-Farrokhran, S., Gill, D., Walker, J., Rakekhi, R., Bozorgnia, B., Amanullah, A. Myocardial injury and COVID-19: Possible mechanisms; Life Sci. 2020 Jul 15; 253: 117723; Published online 2020 Apr 28. doi: 10.1016/j.lfs.2020.117723

Donoghue, M., Hsieh, F., Baronas, E., Godbut, K., Gosselin, M., Stagliano, N., et al., A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 87, E1-E9 (2000). 10.1161/01.RES.87.5. e1.

Zhao, Y., Zhao, Z., Wang, Y., Zhou, Y., Ma, Y., Zuo, W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv 2020.0126.919985 [Preprint]. 26 January 2020. 10.1101/2020.01.26.919985.10.1101/2020.01.26.919985.

Zisman, L. S., Keller, R. S., Weaver, B., Lin, Q., Speth, R., Bristow, M. R. Increased angiotensin-(1-7)–forming activity in failing human heart ventricles: Evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. Circulation 108, 1707-1712 (2003). 10.1161/01.CIR.0000094734.67990.99.

Raizada, M. K., Ferreira, A. J. ACE2: A new target for cardiovascular disease therapeutics. J. Cardiovasc. Pharmacol. 2007; 50: 112-119. 10.1097/FJC.0b013e3180986219.

Epelman, S., Tang, W. H., Chen, S. Y., Lente, F., Francis, G. S., Sen, S. Detection of soluble angiotensin converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol. 2008; 52: 750-754.

Wu, Z., and Mc-Googan, J. M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Centre for Disease Control and Prevention. JAMA. 2020, 10.1001/jama.2020.2648.

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C- L., Abiona, O., Graham, B. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science eabb2507 (2020). 10.1126/science. abb2507.

Zhang, P., Zhu, L., Cai, J., Lei, F., Qin, J., Xie, J., et al., Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients with Hypertension Hospitalized With COVID-19; Circ Res. 2020 Jun 5; 126(12): 1671-1681. Published online 2020 Apr 17. doi: 10.1161/CIRCRESAHA.120.317134.

Ren, Z., Hu, R., Wang, Z., Zhang, M., Ruan., Y., Wu, Z., et al., Epidemiologic and clinical characteristics of heart transplant recipients during the 2019 corona virus outbreak in Wuhan, China: A descriptive survey report; J Heart Lung Transplant; 2020 May; 39(5): 412-417; doi: 10.1016/j.healun.2020.03.008. Epub 2020 Mar 25.

Tomasoni D., Italia, L., Adamo, M., Inciardi, R., Lombardi, C.M., Solomon, S.D., et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease; Eur J Heart Fail; 2020 May 15;10.1002/ejhf.1871; doi: 10.1002/ejhf.1871.

Downloads

Published

2021-01-01

How to Cite

1.
V P, B. Raja R, Nair AB. Cardiac injury and COVID-19: A Review on available present-day literature. Biomedicine [Internet]. 2021Jan.1 [cited 2021Feb.27];40(4):420-8. Available from: https://biomedicineonline.org/index.php/home/article/view/308